解毒化瘀温阳法重建HBV相关肝衰竭免疫平衡的探索与实践

舒发明; 黄英; 毛德文

doi:10.3969/j.issn.1001-5256.2023.11.023

解毒化瘀温阳法重建HBV相关肝衰竭免疫平衡的探索与实践

DOI: 10.3969/j.issn.1001-5256.2023.11.023

舒发明^{1, 2},
黄英³,
毛德文^{1, 2, , ,}

1.
广西中医药大学第一临床医学院，南宁 530200
2.
广西中医药大学第一附属医院肝病科，南宁 530023
3.
广西中医药大学附属国际壮医医院中医科，南宁 530001

基金项目:

国家自然科学基金面上项目 (82274434);

国家自然科学基金 (81960841);

广西中医药多学科交叉创新团队项目 (GZKJ2306);

广西壮族自治区中青年教师基础能力提升项目 (2019KY0336);

广西壮族自治区中青年教师基础能力提升项目 (2021KY0324)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：舒发明负责设计论文框架，起草论文；黄英负责修订论文；毛德文提供文章思路，并对文章进行修改，终审论文。

详细信息

通信作者:
毛德文， mdwboshi2005@163.com （ORCID： 0000-0001-9438-9325）

计量
- 文章访问数: 151
- HTML全文浏览量: 48
- PDF下载量: 12
- 被引次数: 0
出版历程
- 收稿日期: 2023-03-22
- 录用日期: 2023-04-18
- 出版日期: 2023-11-28

Exploration and practice of the detoxicating， stasis-resolving， and Yang-warming method in reconstructing immune balance in hepatitis B virus-related liver failure

Faming SHU^{1, 2},
Ying HUANG³,
Dewen MAO^{1, 2
, ,
,}

1.
First Clinical Medical College，Guangxi University of Chinese Medicine，Nanning 530200
2.
Department of Hepatology，The First Affiliated Hospital of Guangxi University of Chinese Medicine，Nanning 530023，China
3.
Department of Traditional Chinese Medicine，Guangxi International Zhuang Medicine Hospital Affiliated to Guangxi University of Chinese Medicine，Nanning 530001，China

Research funding:

National Natural Science Foundation of China（General Program） (82274434);

National Natural Science Foundation of China (81960841);

Guangxi Traditional Chinese Medicine Multidisciplinary Cross Innovation Team Project (GZKJ2306);

The Basic Ability Enhancement Program for Young and Middle-aged Teachers of Guangxi (2019KY0336);

The Basic Ability Enhancement Program for Young and Middle-aged Teachers of Guangxi (2021KY0324)

More Information

Corresponding author: MAO Dewen， mdwboshi2005@163.com （ORCID： 0000-0001-9438-9325）

摘要

摘要: 肝衰竭为肝病领域的急危重症之一，我国肝衰竭主要由HBV感染所引起。毛德文教授在运用“解毒化瘀温阳法”防治HBV相关肝衰竭基础、临床研究等方面成效突出，尤以“解毒化瘀温阳法”为技术核心的HBV相关肝衰竭免疫平衡重建临床防治新方案的创建奠定了中西医协同治疗HBV相关肝衰竭的基石，彰显了中医药的疗效优势，突破了当前HBV相关肝衰竭临床治疗的瓶颈，为肝衰竭发病率和病死率的降低做出了有益的尝试。
- 肝功能衰竭 /
- 乙型肝炎病毒 /
- 解毒化瘀温阳法 /
- 免疫调节
Abstract: Liver failure is an acute and critical disease in the field of liver diseases， and liver failure in China is mainly caused by hepatitis B virus （HBV） infection. Professor Mao Dewen has made remarkable achievements in the prevention and treatment of HBV-related liver failure in basic and clinical research by using the detoxicating， stasis-resolving， and Yang-warming method， and in particular， with this method as the technical core， the new clinical prevention and treatment regimen for reconstructing immune balance in HBV-related liver failure lays a foundation for synergistic integrated traditional Chinese and Western medicine therapy for HBV-related liver failure， highlights the therapeutic advantages of traditional Chinese medicine， and makes breakthroughs in the technical and therapeutic bottlenecks of current clinical treatment of HBV-related liver failure， thereby attempting to reduce the incidence and mortality rates of liver failure.
- Liver Failure /
- Hepatitis B virus /
- Stasis Removing and Yang Warming Method /
- Immunomodulation

HTML全文

图 1 中医“证”宏观评估肝衰竭免疫功能涨落变化

Figure 1. The key technique for macroscopic evaluation of liver failure immune function fluctuation in traditional Chinese medicine “Syndrome”

下载: 全尺寸图片幻灯片

图 2 解毒化瘀温阳法重建HBV相关肝衰竭免疫平衡关键方案

Figure 2. The key technique for macroscopic evaluation of on rebuilding the immune balance of HBV -related liver failure by detoxifying， removing blood stasis and warming yang

下载: 全尺寸图片幻灯片

参考文献(26)

[1]	NANCHAL R, SUBRAMANIAN R, KARVELLAS CJ, et al. Guidelines for the management of adult acute and acute-on-chronic liver failure in the ICU: Cardiovascular, endocrine, hematologic, pulmonary, and renal considerations[J]. Crit Care Med, 2020, 48( 3): e173- e191. DOI: 10.1097/CCM.0000000000004192.
[2]	ZHANG H, JIA L, YAO SW, et al. Value of MELD combined with serum sodium concentration in predicting the short-term outcome of patients with HBV-related acute-on-chronic liver failure in China: A meta-analysis[J]. J Clin Hepatol, 2018, 34( 9): 1950- 1955. DOI: 10.3969/j.issn.1001-5256.2018.09.024. 张辉, 贾雷, 姚士伟, 等. MELD-Na评分对我国HBV相关慢加急性肝衰竭短期预后预测价值的Meta分析[J]. 临床肝胆病杂志, 2018, 34( 9): 1950- 1955. DOI: 10.3969/j.issn.1001-5256.2018.09.024.
[3]	ZHU Y. Professor Wang Chengbai’s experience in treating severe jaundiced liver disease with promoting qi and promoting blood circulation drugs[J]. Chin J Integr Tradit West Med Liver Dis, 2011, 21( 2): 105- 108. DOI: 10.3969/j.issn.1005-0264.2011.02.018. 朱云. 汪承柏教授重用行气活血药治疗重度黄疸肝病经验[J]. 中西医结合肝病杂志, 2011, 21( 2): 105- 108. DOI: 10.3969/j.issn.1005-0264.2011.02.018.
[4]	LI XH. Professor Qian Ying’s considerations and strategies on treatment of chronic severe hepatitis by blocking and reversing therapy[J]. Shanghai J Tradit Chin Med, 2007, 41( 1): 1- 4. DOI: 10.3969/j.issn.1007-1334.2007.01.001. 李秀惠. 钱英教授“截断逆挽法”治疗慢性重型肝炎的思路与方法[J]. 上海中医药杂志, 2007, 41( 1): 1- 4. DOI: 10.3969/j.issn.1007-1334.2007.01.001.
[5]	ZHANG QY, LI XH, QIAN Y, et al. Professor QIAN Ying’s experience on the treatment of chronic severe viral hepatitis[J]. J New Chin Med, 2005, 37( 3): 14- 15. DOI: 10.3969/j.issn.0256-7415.2005.03.005. 张秋云, 李秀惠, 钱英, 等. 钱英教授治疗慢性病毒性重型肝炎经验介绍[J]. 新中医, 2005, 37( 3): 14- 15. DOI: 10.3969/j.issn.0256-7415.2005.03.005.
[6]	CHEN NS, SUN KW. Speedy treatment of serious hepatitis[J]. J New Chin Med, 2001, 33( 1): 3- 4. DOI: 10.3969/j.issn.0256-7415.2001.01.001. 谌宁生, 孙克伟. 重症肝炎从快速截断论治[J]. 新中医, 2001, 33( 1): 3- 4. DOI: 10.3969/j.issn.0256-7415.2001.01.001.
[7]	CHENG HB. Academic discussion on professor ZHOU Zhongying’s thoughts of“Epidemic Toxin”[J]. J Tradit Chin Med, 2021, 62( 7): 564- 567. DOI: 10.13288/j.11-2166/r.2021.07.003. 程海波. 周仲瑛“疫毒”学术思想探析[J]. 中医杂志, 2021, 62( 7): 564- 567. DOI: 10.13288/j.11-2166/r.2021.07.003.
[8]	LYU C, MAO DW, SHI QL, et al. Experience of MAO Dewen treating hepatic failure with the theory of“Toxin-Turbid causing liver failure”[J]. Liaoning J Tradit Chin Med, 2021, 48( 11): 35- 38. DOI: 10.13192/j.issn.1000-1719.2021.11.009. 吕超, 毛德文, 石清兰, 等. 毛德文“毒邪-毒浊致病”学说治疗肝衰竭经验撷菁[J]. 辽宁中医杂志, 2021, 48( 11): 35- 38. DOI: 10.13192/j.issn.1000-1719.2021.11.009.
[9]	Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007. 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
[10]	LIU P. Current status of research on the pathogenesis of liver failure[J]. Chin J Pract Intern Med, 2005, 25( 9): 780- 781. DOI: 10.3969/j.issn.1005-2194.2005.09.007. 刘沛. 肝衰竭发生机制研究现状[J]. 中国实用内科杂志, 2005, 25( 9): 780- 781. DOI: 10.3969/j.issn.1005-2194.2005.09.007.
[11]	YE YN, GAO ZL. Three shock hypotheses that my induce liver failure[J]. Infect Dis Info, 2009, 22( 5): 276- 279. DOI: 10.3969/j.issn.1007-8134.2009.05.006. 叶一农, 高志良. 乙型肝炎肝衰竭发生机制中的三重打击[J]. 传染病信息, 2009, 22( 5): 276- 279. DOI: 10.3969/j.issn.1007-8134.2009.05.006.
[12]	XU HQ, LI X, TANG SH. Research advances in the role of inflammatory response and related treatment strategies in acute-on-chronic liver failure[J]. J Clin Hepatol, 2022, 38( 8): 1927- 1930. DOI: 10.3969/j.issn.1001-5256.2022.08.041. 徐华谦, 李雪, 汤善宏. 炎症反应在慢加急性肝衰竭中的作用及治疗策略[J]. 临床肝胆病杂志, 2022, 38( 8): 1927- 1930. DOI: 10.3969/j.issn.1001-5256.2022.08.041.
[13]	DENG TT, LI L, GUAN Y, et al. Research advances in inflammatory markers in predicting the prognosis of patients with HBV-related acute-on-chronic liver failure[J]. J Clin Hepatol, 2022, 38( 10): 2346- 2351. DOI: 10.3969/j.issn.1001-5256.2022.10.028. 邓婷婷, 李莉, 关瀛, 等. 炎性相关标志物判断HBV相关慢加急性肝衰竭预后的研究进展[J]. 临床肝胆病杂志, 2022, 38( 10): 2346- 2351. DOI: 10.3969/j.issn.1001-5256.2022.10.028.
[14]	LI XD, XU DP. Immunopathogenesis of acute-on-chronic hepatitis B liver failure[J]. J Prac Hepatol, 2015, 18( 3): 317- 320. DOI: 10.3969/j.issn.1672-5069.2015.02.030. 李晓东, 徐东平. HBV相关慢加急性肝衰竭免疫病理发病机制研究进展[J]. 实用肝脏病杂志, 2015, 18( 3): 317- 320. DOI: 10.3969/j.issn.1672-5069.2015.02.030.
[15]	GWAK GY, KOH KC, KIM HY. Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate[J]. Clin Exp Rheumatol, 2007, 25( 6): 888- 889.
[16]	WANG XJ, ZHANG XP, NING Q. Immune-mediated liver failure[J]. J Clin Hepatol, 2014, 30( 10): 984- 991. DOI: 10.3969/j.issn.1001-5256.2014.10.004. 王晓晶, 张小平, 宁琴. 肝衰竭的免疫发病机制[J]. 临床肝胆病杂志, 2014, 30( 10): 984- 991. DOI: 10.3969/j.issn.1001-5256.2014.10.004.
[17]	LI Y, CAI YM. Analysis on composition of syndrome name[J]. China J Chin Med, 2022, 37( 11): 2322- 2325. DOI: 10.16368/j.issn.1674-8999.2022.11.414. 李奕, 蔡永敏. 证名构成解析[J]. 中医学报, 2022, 37( 11): 2322- 2325. DOI: 10.16368/j.issn.1674-8999.2022.11.414.
[18]	HE FJ. Study on constitution of Traditional Chinese Medicine and proteomics on severe exacerbation of chronic hepatitis B[D]. Nanning: Guangxi University of Traditional Chinese Medicine, 2018. 何发娟. 慢性乙型肝炎重症化倾向期中医体质类型及蛋白质组学的调查研究[D]. 南宁: 广西中医药大学, 2018.
[19]	LONG FL, CHEN XM, WANG N, et al. Study on the intervention of detoxicating and stasis-resolving granules on the prognosis of acute-on-chronic liver failure based on the expression Ratio of IL-17 on CD4⁺T Cells[J]. Lishizhen Med Mater Med Res, 2017, 28( 4): 796- 798. DOI: 10.3969/j.issn.1008-0805.2017.04.010. 龙富立, 陈小明, 王娜, 等. 基于IL-17在CD4⁺T细胞表达比例观察解毒化瘀颗粒对慢加急性肝衰竭预后干预的研究[J]. 时珍国医国药, 2017, 28( 4): 796- 798. DOI: 10.3969/j.issn.1008-0805.2017.04.010.
[20]	WANG XF, ZHONG YQ, ZHANG RZ, et al. Effect of Wenyang Huazhuo Tuihuang decoction on hepatitis B-related acute-on-chronic liver failure[J]. J Emerg Tradit Chin Med, 2019, 28( 9): 1540- 1542, 1546. DOI: 10.3969/j.issn.1004-745X.2019.09.010. 王秀峰, 钟云青, 张荣臻, 等. 温阳化浊退黄汤治疗乙肝相关慢加急性肝衰竭的临床研究[J]. 中国中医急症, 2019, 28( 9): 1540- 1542, 1546. DOI: 10.3969/j.issn.1004-745X.2019.09.010.
[21]	CHEN YQ, MAO DW, TANG N, et al. Efficacy of modified yinchen sini tang in acute-on-chronic liver failure[J]. Chin J Exp Med Formul, 2015, 21( 18): 163- 166. DOI: 10.13422/j.cnki.syfjx.2015180163. 陈月桥, 毛德文, 唐农, 等. 茵陈四逆汤加减治疗慢加急性肝衰竭[J]. 中国实验方剂学杂志, 2015, 21( 18): 163- 166. DOI: 10.13422/j.cnki.syfjx.2015180163.
[22]	MAO DW, LONG FL, SHENG QS, et al. Clinical study on the treatment of endotoxemia in chronic severe hepatitis with detoxicating and stasis-resolving granules[J]. J Sichuan Tradit Chin Med, 2013, 31( 6): 78- 80. 毛德文, 龙富立, 盛庆寿, 等. 解毒化瘀颗粒治疗慢性重型肝炎内毒素血症的临床研究[J]. 四川中医, 2013, 31( 6): 78- 80.
[23]	WANG MG, MAO DW, ZHANG RZ, et al. Experimental study on the regulation of Cadd45a expression in hepatocytes of acute liver failure rats by detoxicating and stasis-resolving granules[J]. Lishizhen Med Mater Med Res, 2016, 27( 10): 2350- 2352. DOI: 10.3969/j.issn.1008-0805.2016.10.015. 王明刚, 毛德文, 张荣臻, 等. 解毒化瘀颗粒调控急性肝衰竭大鼠肝细胞Cadd45a表达的实验研究[J]. 时珍国医国药, 2016, 27( 10): 2350- 2352. DOI: 10.3969/j.issn.1008-0805.2016.10.015.
[24]	QIN YX, MA YZ, JIANG Q, et al. Protective effect of detoxicating and stasis-resolving granules against D-galactosamine/lipopolysaccharide-induced acute liver failure in rats and its mechanism of action[J]. Hunan J Tradit Chin Med, 2018, 34( 12): 113- 116. DOI: 10.16808/j.cnki.issn1003-7705.2018.12.049. 覃艳新, 马玉珍, 蒋琴, 等. 解毒化瘀颗粒对D-半乳糖胺/脂多糖诱导急性肝衰竭大鼠的保护作用及机制研究[J]. 湖南中医杂志, 2018, 34( 12): 113- 116. DOI: 10.16808/j.cnki.issn1003-7705.2018.12.049.
[25]	CASTILLO-DELA CRUZ P, WANEK AG, KUMAR P, et al. Intestinal IL-17R signaling constrains IL-18-driven liver inflammation by the regulation of microbiome-derived products[J]. Cell Rep, 2019, 29( 8): 2270- 2283.e7. DOI: 10.1016/j.celrep.2019.10.042.
[26]	WANG TS, WANG N, ZHANG RZ, et al. Role of immune response and inflammatory injury in the pathogenesis of liver failure[J]. J Clin Hepatol, 2020, 36( 6): 1415- 1419. DOI: 10.3969/j.issn.1001-5256.2020.06.050. 王挺帅, 王娜, 张荣臻, 等. 免疫反应与炎症损伤在肝衰竭发病机制中的作用[J]. 临床肝胆病杂志, 2020, 36( 6): 1415- 1419. DOI: 10.3969/j.issn.1001-5256.2020.06.050.